1. Home
  2. VYGR vs CHMG Comparison

VYGR vs CHMG Comparison

Compare VYGR & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • CHMG
  • Stock Information
  • Founded
  • VYGR 2013
  • CHMG 1833
  • Country
  • VYGR United States
  • CHMG United States
  • Employees
  • VYGR N/A
  • CHMG N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • CHMG Major Banks
  • Sector
  • VYGR Health Care
  • CHMG Finance
  • Exchange
  • VYGR Nasdaq
  • CHMG Nasdaq
  • Market Cap
  • VYGR 206.9M
  • CHMG 239.3M
  • IPO Year
  • VYGR 2015
  • CHMG N/A
  • Fundamental
  • Price
  • VYGR $4.24
  • CHMG $52.31
  • Analyst Decision
  • VYGR Strong Buy
  • CHMG Hold
  • Analyst Count
  • VYGR 7
  • CHMG 3
  • Target Price
  • VYGR $14.50
  • CHMG $56.33
  • AVG Volume (30 Days)
  • VYGR 678.8K
  • CHMG 7.7K
  • Earning Date
  • VYGR 08-06-2025
  • CHMG 10-21-2025
  • Dividend Yield
  • VYGR N/A
  • CHMG 2.44%
  • EPS Growth
  • VYGR N/A
  • CHMG N/A
  • EPS
  • VYGR N/A
  • CHMG 2.38
  • Revenue
  • VYGR $42,580,000.00
  • CHMG $82,641,000.00
  • Revenue This Year
  • VYGR N/A
  • CHMG N/A
  • Revenue Next Year
  • VYGR $107.07
  • CHMG $32.65
  • P/E Ratio
  • VYGR N/A
  • CHMG $22.03
  • Revenue Growth
  • VYGR N/A
  • CHMG N/A
  • 52 Week Low
  • VYGR $2.65
  • CHMG $40.71
  • 52 Week High
  • VYGR $8.28
  • CHMG $55.73
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 70.98
  • CHMG 50.69
  • Support Level
  • VYGR $3.32
  • CHMG $52.77
  • Resistance Level
  • VYGR $3.49
  • CHMG $54.77
  • Average True Range (ATR)
  • VYGR 0.23
  • CHMG 0.84
  • MACD
  • VYGR 0.06
  • CHMG 0.06
  • Stochastic Oscillator
  • VYGR 94.03
  • CHMG 48.54

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About CHMG Chemung Financial Corp

Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.

Share on Social Networks: